FindTrial
Sign In

CT-322

DRUG5 trials

Sponsors

Adnexus, A Bristol-Myers Squibb R&D Company, Bristol-Myers Squibb

Conditions

Brain and Central Nervous System TumorsCancerColorectal Cancer (CRC)Glioblastoma MultiformeNon-small Cell Lung Cancer (NSCLC)Recurrent Glioblastoma Multiforme

Phase 1

CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma
CompletedNCT00374179
Adnexus, A Bristol-Myers Squibb R&D CompanyCancer
Start: 2006-08-31End: 2009-02-28Updated: 2009-02-24
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
NCT00768911
Adnexus, A Bristol-Myers Squibb R&D CompanyGlioblastoma Multiforme
Start: 2008-10-31End: 2011-06-30Target: 30Updated: 2010-10-27

Phase 2

CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
NCT00562419
Adnexus, A Bristol-Myers Squibb R&D CompanyBrain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
Start: 2007-10-31End: 2011-12-31Target: 72Updated: 2010-10-27
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
CompletedNCT00851045
Bristol-Myers SquibbColorectal Cancer (CRC)
Start: 2009-10-31End: 2011-10-31Updated: 2015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
TerminatedNCT00850577
Bristol-Myers SquibbNon-small Cell Lung Cancer (NSCLC)
Start: 2009-06-30End: 2013-08-31Updated: 2015-10-12